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Introduction: Fluorescence in situ hybridization (FISH) is currently 
the standard for diagnosing anaplastic lymphoma kinase (ALK)-
rearranged (ALK+) lung cancers for ALK inhibitor therapies. ALK 
immunohistochemistry (IHC) may serve as a screening and alterna-
tive diagnostic method. The Canadian ALK (CALK) study was initi-
ated to implement a multicenter optimization and standardization of 
laboratory developed ALK IHC and FISH tests across 14 hospitals.
Methods: Twenty-eight lung adenocarcinomas with known ALK 
status were used as blinded study samples. Thirteen laborato-
ries performed IHC using locally developed staining protocols 
for 5A4, ALK1, or D5F3 antibodies; results were assessed by 
H-score. Twelve centers conducted FISH using protocols based 
on Vysis’ ALK break-apart FISH kit. Initial IHC results were 
used to  optimize local IHC protocols, followed by a repeat IHC 
study to assess the results of standardization. Three laboratories 
conducted a prospective parallel IHC and FISH analysis on 411 
consecutive clinical samples using post-validation optimized 
assays.
Results: Among study samples, FISH demonstrated 22 consensus 
ALK+ and six ALK wild type tumors. Preoptimization IHC scores 
from 12 centers with 5A4 and the percent abnormal cells by FISH 
from 12 centers showed intraclass correlation coefficients of 0.83 and 
0.68, respectively. IHC optimization improved the intraclass correla-
tion coefficients to 0.94. Factors affecting FISH scoring and outliers 
were identified. Post-optimization concurrent IHC/FISH testing in 
373 informative cases revealed 100% sensitivity and specificity for 
IHC versus FISH.
Conclusions: Multicenter standardization study may accelerate the 
implementation of ALK testing protocols across a country/region. 
Copyright © 2014 by the International Association for the Study of Lung 
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Our data support the use of an appropriately validated IHC assay to 
screen for ALK+ lung cancers.
Key Words: ALK testing, Immunohistochemistry, Standardization, 
Fluorescence in situ hybridization, reverse-transcriptase polymerase 
chain reaction
(J Thorac Oncol. 2014;9: 1255–1263)
It is estimated that in approximately 3–5% of advanced lung adenocarcinoma patients, anaplastic lymphoma kinase (ALK) 
gene rearrangement is the oncogenic driver of tumor progres-
sion.1–3 Agents that inhibit the activity of aberrant ALK fusion 
receptor proteins have been shown to yield impressive clinical 
responses.4–7 The development of efficient and reliable labora-
tory tests is critical in the selection of patients likely to respond 
to these targeted agents. The standard criterion for detection 
of ALK gene rearrangements is by fluorescence in situ hybrid-
ization (FISH) using the US FDA-approved ALK break-apart 
FISH Probe kit (Abbott Molecular, Abbott Park, IL). However, 
this assay is resource and cost-intensive, especially as a screen-
ing tool, given the low prevalence of ALK rearrangements in 
non-squamous non–small-cell lung cancer (NSCLC) patients. 
Recent evidence suggests that ALK immunohistochemistry 
(IHC) protocols can be optimized to be highly sensitive and 
can identify most ALK-rearranged (ALK+) tumors expressing 
the fusion ALK protein,8–10 potentially providing a less costly 
testing platform that is available widely and used extensively in 
routine pathology practice worldwide.
In anticipation of the availability of ALK inhibitor ther-
apy in Canada, a network of pulmonary and molecular patholo-
gists working in cancer centers across Canada was formed to 
address the challenge of standardization and optimization of 
tests for detection of ALK+ lung cancers. The main goal of 
the Canadian ALK (CALK) study was to establish the feasi-
bility of implementing optimal clinical testing methods and 
algorithms for routine diagnostic detection of ALK+ lung can-
cer based on a multi-laboratory and countrywide collaborative 
approach. We describe here the strategy and processes used to 
generate reference materials and to optimize and standardize 
protocols across a large number of participating centers, and 
we report the results of routine clinical ALK testing across 
Canada for advanced non-squamous NSCLC after CALK 
study completion.
MATERIALS AND METHODS
The overall CALK study schema is shown in 
Supplementary Figure S1 (Supplemental Digital Content 1, 
http://links.lww.com/JTO/A623). Phase 1 included identi-
fication of study cases, phase 2 involved protocol optimiza-
tion and standardization of both FISH and IHC, and phase 
3 conducted prospective concurrent screening of clinically 
advanced non-squamous NSCLC cases using the standardized 
IHC and FISH assays.
Study Samples
Surgically resected NSCLC tumors were selected for this 
study, as they provide the large quantities of tumor tissue required 
for multicenter studies. After approval by the Research Ethics 
Boards of participating institutions, eight pathology depart-
ments participated in retrieving ~2000 resected lung adenocar-
cinoma paraffin blocks to construct tissue microarrays (TMAs) 
for rapid screening of ALK+ cases by IHC and FISH (supple-
mentary Figure S1, Supplemental Digital Content 1, http://
links.lww.com/JTO/A623). A reference study set of 28 cases 
cases, 22 ALK+ and six ALK wild type (−) was assembled from 
the original blocks at a central laboratory, by re-embedding a 
1 × 1 cm original tissue into new blocks and labeled as CALK 
1–28. Twenty samples of non-neoplastic lung tissue containing 
bronchi or bronchioles were assembled into five control blocks 
labeled CALK N1-N5.
IHC Studies
Participating centers used one or more automated IHC 
staining systems manufactured by Dako (Carpinteria, CA), 
Ventana (Tucson, AZ), and Leica (Buffalo Grove, IL) already 
available in their respective clinical laboratories, and one or 
more of the three commercially available antibodies: 5A4 
(Novocastra, Newcastle, United Kingdom), ALK1 (Dako), 
and D5F3 (Cell Signaling, Danvers, MA) in combination with 
a variety of amplified detection methods (Supplementary Table 
S1, Supplemental Digital Content 2, http://links.lww.com/
JTO/A623). For initial screening of the TMAs, N-Histofine 
ALK Detection Kit (Nichirei Biosciences, Tokyo, Japan) was 
also used.
The first round of preoptimization IHC on the study 
set was performed using protocols developed by each labo-
ratory independently, based on published methods.11–13 For 
each case, the participating center pathologist recorded the 
percentage (%) of tumor cells showing each staining inten-
sity (I: 0, 1+, 2+, and 3+). The H-score was calculated using 
the formula of: ∑ = 1 × (%1+) + 2 × (%2+) + 3 × (%3+), 
resulting in scores ranging from 0 to 300. After each site 
pathologists submitted their scores to the study lead inves-
tigator (M.S.T.) and biostatistician (M.P.) for analysis, the 
pathologists met and compared their respective stained sec-
tions. After it was determined that results of several labo-
ratories could be further improved, a protocol optimization 
procedure was developed. An optimization TMA block that 
included selected samples with negative (0), weakly (1+), 
moderately (2+), and strongly (+3)-positive ALK staining 
as determined by an IHC protocol demonstrating optimal 
performance for FISH results was also prepared and distrib-
uted for local adjustment. The protocols were considered 
optimized after all laboratories achieved comparable results 
using the standardized controls.
FISH Studies
ALK FISH testing was performed using the Vysis ALK 
break-apart probe set (Abbott Molecular, Abbott Park, IL) and 
the FDA-approved protocol.14 Before the initiation of FISH 
analysis, technologists and pathologists directly involved in 
FISH scoring were provided hands-on training by the manu-
facturer at a centralized training site. A detailed summary of 
scoring procedures, score sheets, and unstained whole section 
slides of the study cases were distributed to each participating 
1257Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 9, September 2014 Multicenter Standardization of ALK Testing
site. To conserve tissue, a DVD containing whole-slide images 
(.svs format) of the hematoxylin and eosin (H&E)-stained sec-
tions of each case, scanned using the Aperio ScanScope system 
(Vista, CA), was provided. The participating laboratories were 
instructed to use these H&E images to guide FISH analysis, by 
having a pathologist print the low-power images and circle the 
tumor area to be scored.
Fluorescent signal analysis was performed manually 
on fluorescence microscopes at each participating site. Red, 
green, and fusion signals (defined as red and green signal 
≥ 2 signal-widths apart) were counted in a total of 200 (100/
person) non-overlapping, intact interphase nuclei per tumor, 
by two trained technologists and/or pathologists per center. 
The scoring protocol involved scanning the slide and choosing 
two or more representative high-power fields to score, includ-
ing areas suspicious for rearrangement if possible, and scor-
ing eligible tumor nuclei in a consecutive manner within each 
field, before moving to the next field. Combined counts at each 
participating site were provided to the study biostatistician for 
data analysis.
RT-qPCR Assay
RT-qPCR was carried out as previously reported,15 
with detailed methods and primer sequences provided in 
Supplementary Materials (SDC, http://links.lww.com/JTO/
A623).
Multicenter Prospective Parallel 
IHC and FISH Screening
To prospectively assess the sensitivity and specific-
ity of ALK IHC for detecting ALK FISH-positive (FISH+) 
tumors, three centers conducted parallel IHC (5A4 antibody) 
and FISH  testing of 411 consecutive clinical cases using the 
post-standardization protocols. The generally accepted crite-
rion of ≥15% abnormal ALK FISH signals was used to diag-
nose ALK FISH+ tumors. In almost all cases, the optimization 
resulted in background IHC staining being completely absent.
Statistical Analysis of Multicenter results
Descriptive statistics were used to describe quantita-
tively the main features of the data collection. Variability of 
scores for both IHC and FISH was estimated by intraclass cor-
relation (ICC), where an ICC of 0.85 or higher is considered 
to indicate an acceptably reliable test.
RESULTS
Multicenter IHC Correlation
Altogether 13 centers participated, with 12 centers elect-
ing to use the 5A4 antibody and one center to use only the 
ALK1 and D5F3 antibody. Seven centers used the Ventana 
Benchmark XT/Ultra, three used the Leica Bond III/Max sys-
tem, and four used the Dako Autostainer (Supplementary Table 
S1, Supplemental Digital Content 2, http://links.lww.com/JTO/
A623). One center also evaluated the ALK-1 antibody using the 
Ultraview system on BenchMark, whereas three centers evalu-
ated the D5F3 antibody using the Autostainer and Advanced or 
Flex+ systems or the BenchMarkXT. Representative images of 
tumors with different staining intensities are shown in Fig. 1A. 
The overall ICC of H-scores for the preoptimization scores 
between centers that evaluated 5A4 was 0.866 (Fig. 1B). After 
optimization, background staining with 5A4 was largely absent, 
with positive tumors showing diffuse staining involving practi-
cally all tumor cells. For eight centers that performed the second 
evaluation after optimization, the ICC of 0.867 from preopti-
mization scores improved to 0.949 after optimization (Fig. 1C 
and Supplementary Figure S2, Supplemental Digital Content 3, 
http://links.lww.com/JTO/A623).
For centers that evaluated two antibodies, the Pearson’s 
correlations between the H-scores for 5A4 with ALK-1 and 
D5F3 were 0.844 and 0.972, respectively (Supplementary 
Figure S3, Supplemental Digital Content 4, http://links.lww.
com/JTO/A623). For three centers that evaluated D5F3, cor-
relation between their respective D5F3 H-scores with the 
mean of 5A4 scores from across 12 centers or with their 
own 5A4 scores ranged from 0.863 to 0.978 (Supplementary 
Figure S4, Supplemental Digital Content 5, http://links.lww.
com/JTO/A623). Some background staining was noted often 
with D5F3, especially in macrophages and airway epithelial 
cells.
Multicenter FISH Correlation
FISH counts were obtained from 12 participating cen-
ters. Results were obtained from all centers for 21 of 28 
(75%) of tumors and 19 of 20 (95%) of the normal tissues. 
The FISH patterns seen in the tumors can be roughly grouped 
into five major patterns: negative/normal (Fig. 2A), negative 
with extra copies of ALK (Fig. 2B), positive with classical 
split signals (Fig. 2C), and positive with loss of the 5′ (green) 
probe (Fig. 2D). A consensus FISH result was clear in all 
28 tumor samples, with complete concordance in 19 (68%) 
tumors (Supplementary Table S4, Supplemental Digital 
Content 8, http://links.lww.com/JTO/A623). Overall, 22 of 
28 tumors were positive for ALK rearrangement and six of 
28 tumors were negative, with the distribution of the tumors 
among these FISH patterns shown in Supplementary Table S2 
(Supplemental Digital Content 6, http://links.lww.com/JTO/
A623). Using the standard cutoff of ≥ 15 % abnormal cells 
and the consensus FISH result as the reference, we observed 
only 14 of 317 (4.4%) FISH outlier results (Supplementary 
Table S3, Supplemental Digital Content 7, http://links.lww.
com/JTO/A623). The overall diagnostic sensitivity of FISH 
across all laboratories in our study was 95.2 %, and speci-
ficity was 95.8%, with a positive predictive value of 99%, 
and negative predictive value of 89%. Figure 2E shows the 
distribution of % abnormal FISH signals for all 28 tumors 
and 20 normal lung tissue across 12 centers. The overall ICC 
among all samples including the normal was 0.83, but was 
only 0.68 among the tumors, illustrating a considerable varia-
tion in the percent abnormal tumor cells scored among the 12 
laboratories.
Of the nine samples with at least one discrepant result, 
six were ALK FISH+, two were ALK FISH−, and one was 
an atypical case (CALK-11) to be discussed further below. 
The false-positive results for the two FISH– cases ranged 
between 20% and 32% abnormal nuclei and for false-negative 
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FIGURE 1.  ALK immunohistochem-
istry (IHC) staining (A) representative 
images of ALK staining intensities (0 
to 3+) for scoring the sections stained 
before multicenter protocol optimiza-
tion. (B) Distribution of the H-scores 
obtained from 12 laboratories across 
28 study cases. Seven cases were 
considered ALK IHC negative by con-
sensus, despite the occasional outlier 
scores. (C) Box-plot of H-scores from 
eight centers that provided both 
preoptimized and post-optimized 
IHC scores.
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cases ranged between 0 and 14.7 % (Supplementary Table 
S4, Supplemental Digital Content 8, http://links.lww.com/
JTO/A623). Upon group review of the cases and feedback on 
consensus results, reasons determined for false FISH− results 
were poor signal quality and tumor cells being lost in deeper 
sections. Other potential reasons for false negatives included 
the lack of physically marked H&E images to guide scor-
ing, as some laboratories reported that the.svs files were too 
awkward to refer to. Potential reasons for false positives were 
poor signal quality, nonadherence to more than or equal to two 
signal-widths for a break-apart, selective scoring of abnormal 
nuclei, and elevated ALK copy number resulting in increased 
artifactual split signals.
Concordance Between IHC and FISH
Consensus FISH and IHC results agreed for 27 of 28 
tumors (Fig. 2E). All normal tissues were scored as negative 
for both FISH and IHC by all centers. Tumor CALK-11 was 
consensus positive by FISH and mostly negative by IHC, with 
very focal weak positive staining noted at a few centers. Upon 
FIGURE 2.  Representative often 
observed ALK break-apart fluores-
cence in situ hybridization images 
and distribution of break-apart 
signals among Canadian Anaplastic 
Lymphoma Kinase (CALK) samples. 
A, A straightforward negative pat-
tern. (B) A negative for ALK rear-
rangement case with multiple copies 
of ALK arising from polysomy and/
or unbalanced structural rearrange-
ments involving chromosome 2. 
(C) A typical ALK inversion pattern, 
with variably extra copies of the ALK 
gene. Arrows point to characteristic 
split signals in adjacent cells. (D) A 
common ALK rearrangement pattern 
where the 5′ ALK probed region has 
been lost, leaving solitary red signals 
without solitary green signals. (E) 
Distribution of all abnormal ALK 
signals from 12 centers according 
to their percentages counted in  
200 nuclei (by two technologists).
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review, CALK-11 demonstrated a unique FISH pattern, with 
three to five fusion signals containing a tiny green component, 
and three to five solitary green signals (Supplementary Figure 
S5, Supplemental Digital Content 9, http://links.lww.com/JTO/
A623). As these tiny green components of the fusion signals 
were poorly visible, all but one laboratory counted these sig-
nals as solitary red signals, and the consensus result was posi-
tive for ALK-rearrangement, with a polysomy pattern. This 
tumor was the only FISH+ case in our study with a negative 
IHC result.
RT-qPCR
The snap-frozen tumor sample from CALK-11 was 
studied using alternate methods. Using primers that detect 
low-level 5′ non-kinase ALK exons (13 of 14 and 17 of 18) 
in normal lung and high-level 3′ kinase ALK exons (22 of 23 
and exons 24 of 26) in tumor cells expressing the ALK fusion 
mRNA, aberrant overexpression of the 3′ transcript was nega-
tive (Supplementary Figure S5, Supplemental Digital Content 
9, http://links.lww.com/JTO/A623). The RNAseq analysis of 
the same tumor RNA also failed to detect the presence of any 
fusion transcript involving the ALK cDNA (data not shown). 
Based on these results, we postulate that the atypical FISH 
pattern with a tiny green signal fused with the “solitary” red 
signals may result from a breakpoint 5′ to the ALK gene caus-
ing the abnormal FISH pattern, but not involving the ALK 
gene itself.
Prospective IHC and FISH Screening
Three centers conducted parallel IHC using the 5A4 anti-
body and the FISH testing of 411 consecutive clinical cases 
using the optimized and validated protocols. The centers scored 
ALK IHC+ when there was diffuse staining of the tumor cells 
clearly distinct from background, and equivocal when focal faint 
staining was noted or in rare cases with background staining that 
made it difficult to decide staining specificity (Supplementary 
Figure S6, Supplemental Digital Content 10, http://links.lww.
com/JTO/A623), thus requiring FISH confirmation for a defini-
tive diagnosis. Cases without tumor cell staining above back-
ground were called IHC−.
Among the 411 cases, 373 (90.8%) were informative by 
both methods and 38 (9.2%) failed FISH testing. FISH unin-
formative cases were because of inadequate residual tumor 
tissue or technical failure. Among the dual informative cases, 
18 (4.8%) were both IHC+/FISH+, 326 (87.4%) tested IHC−/
FISH−; 29 (7.8%) were IHC equivocal/FISH−, all of which 
defaulted to FISH testing for final diagnosis. Of 411 cases, 
two were initially discordant with IHC−/FISH+ (case 8: 22%) 
or “borderline negative” (case 13: 14.5%; Supplementary 
Table S5, Supplemental Digital Content 11, http://links.lww.
com/JTO/A623). In both cases, blinded repeat FISH analyses 
locally and at another center were scored as negative. Among 
the 29 IHC equivocal cases, one case was initially FISH+ (case 
47, 19% split signal), but repeat scoring (2 × 13%) and inde-
pendent testing at another center found it negative (1% signal).
Among the 373 dual informative cases, FISH−/IHC− 
had mean 3.1% (95% confidence interval [CI] 2.7–3.5%) 
abnormal FISH signal counts, FISH+/IHC+ cases had 48.6% 
(95% CI 46.7–50.5%) split-signal, and IHC equivocal cases 
scored 4.0% (95% CI 3.6–4.3%) FISH split-signal. When 
considering IHC equivocal cases as positive, IHC sensitiv-
ity and specificity were 100% (95% CI 81.5–100.0%) and 
91.8% (95% CI 88.5–94.5%), respectively. When equivocal 
cases were considered negative, the sensitivity and specific-
ity of IHC against FISH was 100% (sensitivity 95% CI 81.5–
100.0%; specificity 95% CI 99.0–100.0%).
ALK IHC for Screening ALK-
Rearranged Lung Cancers
Since the completion of the study in May 2012, most 
CALK centers started implementing ALK IHC as the pre-
ferred method to screen clinically, in advanced non-squa-
mous NSCLC patients. All centers performed FISH only on 
cases that the signing pathologist diagnosed as IHC+ or IHC 
equivocal, as described. Through the end of June 2013, 4927 
patients were screened by IHC, representing close to half of 
all advanced non-squamous cases across the country (Fig. 3). 
Among these, 718 (14.6%) cases were FISH tested, with 124 
cases confirmed as FISH+ for ALK rearrangement, represent-
ing an overall prevalence of 2.5%.
FIGURE 3.  Implementation of 
clinical ALK testing in Canada after 
completion of CALK study.
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DISCUSSION
In the CALK study, we have implemented a strategy 
for optimization and standardization of ALK IHC and FISH 
testing nationally across 14 centers in Canada. Aside from its 
practical goal for the multicenter standardization of these tests, 
CALK also demonstrated that high-level correlation between 
centers can be achieved using optimized ALK IHC protocols 
and standardized controls designed to enable the calibration of 
highly sensitive and specific assays, regardless of the antibodies 
or autostainer platform used. We have also demonstrated that 
variation in FISH scoring of aberrant ALK signals may occur 
in laboratories with pretrained technologists, although overall 
ALK FISH testing is very robust. Our concurrent IHC and 
FISH testing of consecutive clinical samples showed that with 
the optimized protocols, diffuse IHC+ staining has 100% sen-
sitivity in detecting true FISH+ ALK tumors, whereas FISH+ 
results with low split-signal count could be false positive when 
IHC is negative. Our results showed that IHC can be deployed 
as a screening method to detect ALK-rearranged lung cancers, 
with rapid uptake of ALK testing across a country. Data also 
suggest that a clearly positive IHC result may be used as a 
diagnostic test to determine ALK+ status. With a relatively low 
prevalence of ALK rearrangements in lung cancer, it is chal-
lenging for individual centers to independently optimize ALK 
testing and gain testing expertize using a large number of posi-
tive controls that may not be available at individual institutions. 
Furthermore, there are very few ALK-rearranged lung cancer 
cell lines available for such purposes, and cell lines alone are 
inadequate to validate FISH cutoff values on paraffin sections. 
Through formation of a pathology network, the CALK multi-
center collaboration addressed these challenges, allowing the 
screening of a large number of resection cases to identify ALK+ 
tumors, and facilitating standardization of results by establish-
ment of reference ranges and test optimization through the cre-
ation of reference sets and common standardized controls.
The CALK study identified several factors that can 
affect the sensitivity and specificity of ALK IHC and FISH 
testing. With respect to IHC, laboratories may vary widely 
in their choice of routine IHC protocols, primary antibody 
and detection system selection, and immunoscoring criteria. 
Protocols producing IHC results that best predicted ALK 
FISH consensus status were considered optimal. Distribution 
of the graded control block provides a common external stan-
dard with which to assess adjustments in individual laboratory 
protocols that are required during optimization and standard-
ization of the IHC assay. Through these efforts, it was possible 
to obtain highly concordant IHC results between testing cen-
ters and with gene rearrangement status by FISH.
Many authorities consider FISH testing as the standard 
test for determining ALK status.16 Camidge et al17 reported 
previously that the mean percentage of signals positive for 
ALK rearrangement in ALK+ tumors was 53.8% (95% CI 
22.2–86.6%), whereas in ALK− tumors was 6.0% (95% 
CI 3.5–9.5%). In our study, a majority of FISH+ cases also 
showed greater than 40% mean positive signals across 12 
reporting laboratories, but occasional outlier scores occurred. 
This was despite involving mostly experienced cancer cytoge-
netic technologists who had undertaken specific pretraining for 
ALK FISH testing. A common pitfall of FISH tests on tumor 
cells is the unintentional scoring of non-tumor cells leading 
to a false-negative result. This problem could be alleviated by 
close guidance and supervision by pathologists on the tumor 
areas to score. This is particularly important for NSCLC, as 
tumors often show significant chronic inflammatory cell infil-
trate and/or stromal fibroblastic reaction that can be difficult 
to distinguish from tumor nuclei with the fluorescence micro-
scope. Our experience also suggests that strict adherence to a 
more than or equal to two signal-width separation for break-
apart signals is crucial. A pathologist should be involved by 
educating the technologists on histology of the sample being 
analyzed, and reviewing cases close to 15% cutoff (10–20%) 
to ensure that the counts are representative of tumor cells.8,18 
Furthermore, there is a need for ongoing proficiency testing 
for ALK FISH and IHC, both centrally organized and between 
collaborating institutions, particularly for cases with a discor-
dant FISH and IHC result.
Although ALK diagnosis by FISH testing is considered 
a standard method for ALK-rearranged lung cancers in the 
United States, screening by IHC has been proposed or adopted 
for clinical practice in many other parts of the world.2,9,13,19 
This strategy would significantly reduce the cost of ALK test-
ing and also expedite its turnaround time, by conducting FISH 
testing only to confirm IHC results. This testing paradigm has 
largely been adopted across Canadian health care institutions. 
This paradigm would work only if highly sensitive ALK IHC 
protocols are developed by using standard controls/calibrators 
confirmed to be suitable to identify FISH+ tumors. Although 
initial IHC equivocal diagnoses could be high at some centers 
(Table 1), this rate will likely decrease significantly as patholo-
gists gain experience in interpreting IHC results and confidence 
TABLE 1.  Concurrent ALK IHC/FISH Analysis Study 
Post-validation
Total FISH− FISH +
FISH  
Uninformativea
Center 1 (n = 99)
 IHC− 96 (97.0%) 95 0 1
 IHC+ 2 (2.0%) 0 2 0
 IHC equivocal 1 (1.0%) 1 0 0
Center 2 (n = 132)
 IHC− 101 (76.5%) 85 0 16
 IHC+ 7 (5.3%) 0 7 0
 IHC equivocal 24 (18.2%) 22 0 2
Center 3 (n = 180)
 IHC− 164 (91.1%) 146 0 18
 IHC+ 10 (5.6%) 0 9 1
 IHC equivocal 6 (3.3%) 6 0 0
Combined (n = 411)
 IHC− 361 (87.8%) 326 0 35
 IHC + 19 (4.6%) 0 18 1
 IHC equivocal 31 (7.6%) 29 0 2
aFISH result was not available because of inadequate residual tumor tissue or 
technical failure. These cases were excluded from analysis of sensitivity and specificity.
FISH, fluorescence in situ hybridization; IHC, immunohistochemistry.
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that focal/weak equivocal staining is consistently associated 
with FISH− results. A review of the literature has identified 
11 studies involving slightly more than 2900 NSCLC cases 
that have been studied by both IHC and FISH (Table 2). 
Although a majority of these studies were retrospective or 
single-institution analyses, among 2690 IHC-negative cases 
reported, only three were found to be FISH+, giving a false-
negative rate of ~0.1%.2,8–10,12,13,18,20–24 As IHC is relatively easy 
to implement clinically and mostly automated, rapid uptake 
of population-wide testing can be readily accelerated and 
achieved, as we have demonstrated in Canada after comple-
tion of the CALK study.
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